Skip to main content
  • Contact us

    • Absorbable sutures

    Main advantage of absorbable sutures

    The major advantage of absorbable sutures is the absence of foreign bodies in living tissue after a few months, without any additional intervention.

    Technically, absorbable sutures must have sufficient strength to hold the wound until the tissue has healed sufficiently. Then the absorbable sutures will lose all of their strength and be eliminated by the body’s metabolism or their knot falls outside the body (if it is surface use).

     

    Absorbable sutures characteristics

    • Time for complete loss of strength retention (zero retention): At the end of which the suture fulfills its role of maintaining the edges of a wound (the strength of the thread is close to zero).
    • Total absorption : The time required for complete degradation and complete elimination of the suture from the body.

    Our products

    Optime®

    Request the Brochure 1
    Request the Brochure 2
    • Intended use: Tissue approximation and/or ligation.
    • Composition: Braid of polyglycolic Acid (PGA) and coated with polycaprolactone and calcium stearate or a mixture composed of poly (lactic-co-glycolic acid) (30/70) and calcium stearate. Available in dyed violet or undyed.
    • Residual tensile strength: in vivo approximately 65% after 14 days post-implantation, more than 40% after 21 days.
    • Time of total absorption: 60-90 days
    • Indications: general surgery, ophthalmic surgery.

    Class III medical device for professional surgical use – CE 0459 GMED – Manufacturer : Peters Surgical – Read the instructions carefully before using this device. 

    Optime® R

    Request the Brochure
    • Intended use: Soft tissue approximation when short time wound support is acceptable and when rapid absorption is needed.
    • Composition: Braid of polyglycolic acid (PGA) and coated with polycaprolactone and calcium stearate or a mixture composed of poly (lactic-co-glycolic acid) (30/70) and calcium stearate. Available in undyed.
    • Residual tensile strength: in vivo 40% after 7 days post-implantation, almost zero after 14 days.
    • Time of complete absorption: 42 days
    • Indications: general surgery for skin and mucous membrane closure in pediatrics, stomatology, episiotomies, circumcisions and ophthalmic surgery for conjunctival sutures.

    Class III medical device for professional surgical use – CE 0459 GMED – Manufacturer : Peters Surgical – Read the instructions carefully before using this device

    Advantime®

    Request the Brochure 1
    Request the Brochure 2
    • Intended use: Soft tissue approximation and/or ligation.
    • Composition: Monofilament of poly(glycolide-co-caprolactone) (Polyglecaprone 25). Available in dyed violet and undyed.
    • Residual tensile strength: in vivo greater than 55% after 7 days; 25% after 14 days; almost zero between the third and fourth week of implantation.
    • Time of complete absorption: 90-120 days
    • Indications: general surgery

    Class III medical device for professional surgical use – CE 0459 GMED – Manufacturer : Peters Surgical Read the instructions carefully before using this device

    Monotime®

    Request the Brochure
    • Intended use: Soft tissue approximation and/or ligation, particularly when long time support is required (until six weeks)
    • Composition: Monofilament of polydioxanone (PDO). Available in dyed violet.
    • Residual tensile strength: in vivo 75% after 14 days post-implantation, more than 60% after 28 days, and about 50% after 42 days (six weeks)
    • Time of complete absorption: 180-210 days
    • Indications: general surgery, pediatric cardiac surgery, peripheral vascular surgery, ophthalmic surgery and microsurgery.

    Class III medical device for professional surgical use – CE 0459 GMED – Manufacturer : Peters Surgical – Read the instructions carefully before using this device

    Glactime®

    • Intended use: Tissue approximation and/or ligation.
    • Composition: Braid of copolymer of glycolic and lactic acids (PGLA) and coated with copolymer of glycolic and lactic acids and calcium stearate. Available in dyed violet or undyed.
    • Residual tensile strength: in vivo approximately 65% after 14 days post-implantation, and 40% after 21 days.
    • Time of complete absorption: 56-70 days
    • Indications: general surgery, ophthalmic surgery.

    Class III medical device for professional surgical use – CE 0459 GMED – Manufacturer : Peters Surgical – Read the instructions carefully before using this device

    Sinusorb® PGA

    • Intended use: Soft tissue approximation and/or ligation
    • Composition: Uncoated monofilament or coated braid of homopolymer of glycolic acid (PGA) : Coating composed of a mixture of polycaprolactone and calcium stearate. Available in dyed violet or undyed.
    • Residual tensile strength: in vivo approximately 65% after 14 days post-implantation, more than 40% at 21 days for medium diameter sutures and 30% for small diameter sutures.
    • Time of complete absorption: 60-90 days
    • Indications: general surgery, ophthalmic surgery ; but not for use in cardiovascular and neurological surgery

    Class III medical device for professional surgical use – CE 0459 GMED – Manufacturer : Peters Surgical – Read the instructions carefully before using this device